Dergi makalesi Açık Erişim

The effectiveness of chitosan-mediated silencing of PDGF-B and PDGFR-beta in the mesangial proliferative glomerulonephritis therapy

Alan, Saadet; Salva, Emine; Yilmaz, Ismet; Turan, Suna Ozbas; Akbuga, Julide


Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Alan, Saadet</dc:creator>
  <dc:creator>Salva, Emine</dc:creator>
  <dc:creator>Yilmaz, Ismet</dc:creator>
  <dc:creator>Turan, Suna Ozbas</dc:creator>
  <dc:creator>Akbuga, Julide</dc:creator>
  <dc:date>2019-01-01</dc:date>
  <dc:description>Platelet-derived growth factor-B (PDGF-B) is a growth factor that plays an important role in the progression of mesangial proliferative glomerulonephritis (MsPGN). PDGF-B may contribute to mesangioproliferative changes and is overexpressed in MsPGN. Recently, small interfering RNAs (siRNAs) have been widely used for gene silencing effects in experimental models of renal diseases. Nanoparticle-based therapeutics are preferred for reasons such as increasing therapeutic efficacy and reducing toxic effects caused by high doses. The distribution of nanoparticles to the kidney is a significant advantage in siRNA delivery. The aim of this study was to investigate the efficacy of chitosan/siRNA nanoplexes in silencing of PDGF-B and PDGFR-beta genes in kidney and to decrease mesangial cell proliferation and matrix accumulation in MsPGN model induced by anti-Thy-1.1 antibody. The therapeutic effects of chitosan/siPDGF-B + siPDGFR-beta nanoplexes in glomerulonephritic rats were studied by molecular, biochemical, and histopathologic evaluations. Chitosan/siPDGF-B + siPDGFR-beta nanoplexes markedly reduced PDGF-B and PDGFR-beta mRNA and protein expressions in experimental MsPGN model. Histopathologic examination results showed that the silencing of PDGF-B and its receptor PDGFR-beta led to reduction in mesangial cell proliferation and matrix accumulation. The use of chitosan/siPDGF-B + siPDGFR-beta nanoplexes for silencing the PDGF-B pathway in MsPGN can be considered as a new effective therapeutic strategy.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/68529</dc:identifier>
  <dc:identifier>oai:zenodo.org:68529</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>EXPERIMENTAL AND MOLECULAR PATHOLOGY 110</dc:source>
  <dc:title>The effectiveness of chitosan-mediated silencing of PDGF-B and PDGFR-beta in the mesangial proliferative glomerulonephritis therapy</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>
30
7
görüntülenme
indirilme
Görüntülenme 30
İndirme 7
Veri hacmi 1.7 kB
Tekil görüntülenme 29
Tekil indirme 7

Alıntı yap